<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372772</url>
  </required_header>
  <id_info>
    <org_study_id>No. BSMMU/2017/2668</org_study_id>
    <nct_id>NCT03372772</nct_id>
  </id_info>
  <brief_title>Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients</brief_title>
  <official_title>Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It has been observed that despite administration of apparently adequate thyroid hormone
      replacement in hypothyroid patients, many of them experience persistent fatigue and
      fatigue-related symptoms. Carnitine transports long chain fatty acids into the mitochondria
      whereupon the high energy source (ATP) becomes synthesized. Levocarnitine administration
      reduced fatigue related symptoms in hypothyroid patients receiving thyroid hormone
      replacement. The present study deals with alleviation of fatigue in hypothyroid patients by
      carnitine supplementation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been well-established now-a-days that, some chronic diseases impose generalized
      weakness, lethargy, lassitude amounting from degrees mild, moderate to a severe one to total
      incapacitation on the part of the patients. Hypothyroid patients instate of receiving
      adequate thyroid hormone replacement, experience fatigue-related symptoms. Carnitine is a
      non-essential amino acid synthesized endogenously from essential amino acids- lysine and
      methionine with in the body involved in long chain fatty acid transportation to the
      mitochondrial membrane. Carnitine- transportation system is essential for production of
      energy at cellular level. Thyroid hormone plays an important role in carnitine-dependent long
      chain fatty acid transport and oxidation. Some available reports suggest that, Levocarnitine
      supplementation produced potentially favourable effects on fatigue-related symptoms in
      hypothyroid patients although still awaits confirmation. The present study is an attempt to
      investigate into the effects of Levocarnitine supplementation on fatigue in patients with
      hypothyroidism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Control Group- Patients with only levothyroxine therapy Interventional Group- Patients with Levocarnitine supplementation in addition to levothyroxine therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Alleviation of fatigue level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>8 weeks</time_frame>
    <description>Effect of Levocarnitine on lipid level</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Patient Compliance</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group - patients with only levothyroxine therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention Group- Patients with levocarnitine supplementation in addition to levothyroxine therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocarnitine</intervention_name>
    <description>Levocarnitine syrup- Oral supplementation about 2000mg/ day for 8 weeks</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Levocarnitine syrup</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Clinical diagnosis of primary hypothyroidism patients with fatigue symptoms ii. Age :
        From 20 to 50 years iii. Levothyroxine treatment: receiving for at least 6 months iv. Serum
        free thyroxine level: 0.80-1.80 ng/dl v. Serum Thyroid-stimulating hormone level: 0.35-5.50
        µIU/ml ( µIU = micro international unit)

        Exclusion Criteria:

        i. Patients with Hypothyroidism 20 years and 50 years ii. Acute or chronic liver diseases
        iii. Anaemia iv. Clinical diagnosis of Diabetes mellitus. v. Cardiovascular disease ( such
        as heart failure, arrhythmia and uncontrolled hypertension ) vi. Patients with
        psychological disorders (such as depression, anxiety disorder, schizophrenia, alcoholism or
        fatigue disorder due to other systemic diseases) vii. Patients having serious infections or
        terminal illness (such as tuberculosis, HIV or malignant tumor ) viii. Autoimmune diseases
        ( such as rheumatoid arthritis, Systemic lupus erythematosus or multiple sclerosis) ix.
        Patients with impaired renal function x. Pregnant or planned to be pregnant xi. Nursing
        mothers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farjana Akhter, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident ,Phase-B</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Farjana Akhter, MBBS</last_name>
    <phone>01534615464</phone>
    <email>polynoble@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jasmine Dewan, PHD</last_name>
    <phone>01712533169</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phamacology Department, BSMMU</name>
      <address>
        <city>Dhaka</city>
        <state>Shahbag</state>
        <zip>1000</zip>
        <country>Bangladesh</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farjana Akhter, MBBS</last_name>
      <phone>01534615464</phone>
      <email>polynoble@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jasmine Dewan, PHD</last_name>
      <phone>01712533169</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh</investigator_affiliation>
    <investigator_full_name>Dr. Farjana Akhter</investigator_full_name>
    <investigator_title>Resident ( Phase-B)</investigator_title>
  </responsible_party>
  <keyword>Fatigue, Levocarnitine,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

